Impairment of dynamic thiol–disulphide homeostasis in patients with idiopathic Parkinson's disease and its relationship with clinical stage of disease

Clinical Neurology and Neurosurgery

Volumn 153, Issue , 2017, Pages 50-55

  Vural, Gonul ^a   Gumusyayla, Sadiye ^a   Bektas, Hesna ^b   Deniz, Orhan ^a   Alisik, Murat ^b   Erel, Ozcan ^a  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Oxidative stress; Parkinson's disease; Thiol disulphide homeostasis

Indexed keywords

DISULFIDE; LEVODOPA; THIOL; THIOL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISULFIDE BOND; DYNAMIC THIOL DISULPHIDE HOMEOSTASIS; FEMALE; HOEHN AND YAHR SCALE; HOMEOSTASIS; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; STAGING; AGED; BLOOD; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISULFIDES; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SULFHYDRYL COMPOUNDS;

EID: 85006993205     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2016.12.009     Document Type: Article

References (45)

1. [1] Mayeux, R., Marder, K., Cote, L.J., Denaro, J., Hemenegildo, N., Mejia, H., Tang, M.X., Lantigua, R., Wilder, D., Gurland, B., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan 1988–1993. Am. J. Epidemiol. 142 (1995), 820–827.
2. [2] Lowe, J., Graham, L., Leigh, P.N., Disorders of movement and system degeneration. Graham, D.I., Lantos, P.L., (eds.) Greenfield's Neuropathology, 1997, Arnold, London, 281–366.
3. [3] Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., Marsden, C.D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52 (1989), 1830–1836.
4. [4] Saggu, H., Cooksey, J., Dexter, D., Wells, F.R., Lees, A., Jenner, P., Marsden, C.D., A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 53 (1989), 692–697.
5. [5] Perry, T.L., Godin, D.V., Hansen, S., Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci. Lett. 33 (1982), 305–310.
6. [6] Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., Mizuno, Y., Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 2696–2701.
7. [7] Floor, E., Wetzel, M., Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70 (1998), 268–275.
8. [8] Zhang, J., Perry, G., Smith, M.A., Robertson, D., Olson, S.J., Graham, D.G., Montine, T.J., Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154 (1999), 1423–1429.
9. [9] Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P., Halliwell, B., Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69 (1997), 1196–1203.
10. [10] Fornstedt, B., Brun, A., Rosengren, E., Carlsson, A., The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. Park. Dis. Dement. Sect. 1 (1989), 279–295.
11. [11] Sies, H., (eds.) Oxidative Stress. Introductory Remarks, 1985, Oxidative stress, Academic Press, London, 1.
12. [12] Chinta, S.J., Andersen, J.K., Redox imbalance in parkinson's disease. Biochim. Biophys. Acta 1780 (2008), 1362–1367.
13. [13] Kirbas, A., Kirbas, S., Cure, M.C., Tufekci, A., Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson's disease. J. Clin. Neurosci. 21 (2014), 451–455.
14. [14] Kirbas, A., Kirbas, S., Anlar, O., Efe, H., Yilmaz, A., Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis. J. Clin. Neurosci. 20 (2013), 1106–1109.
15. [15] Sen, C.K., Packer, L., Thiol homeostasis and supplements in physical exercise. Am. J. Clin. Nutr. 72 (2000), 653–669.
16. [16] Turell, L., Radi, R., Alvarez, B., The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic. Biol. Med. 65 (2013), 244–253.
17. [17] Jones, D.P., Liang, Y., Measuring the poise of thiol/disulfide couples in vivo. Free Radic. Biol. Med. 47 (2009), 1329–1338.
18. [18] Erel, O., Neselioglu, S., A novel and automated assay for thiol/disulphide homeostasis. Clin. Biochem. 47 (2014), 326–332.
19. [19] Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48 (2010), 749–762.
20. [20] Biswas, S., Chida, A.S., Rahman, I., Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem. Pharmacol. 71 (2006), 551–564.
21. [21] Gumusyayla, S., Vural, G., Bektas, H., Deniz, O., Neselioglu, S., Erel, O., A novel oxidative stress marker in patients with Alzheimer's disease: dynamic thiol-disulphide homeostasis. Acta Neuropsychiatr. 4 (2016), 1–6.
22. [22] Bektas, H., Vural, G., Gumusyayla, S., Deniz, O., Alisik, M., Erel, O., Dynamic thiol-disulfide homeostasis in acute ischemic stroke patients. Acta Neurol. Belg. 1 (2016), 1–16.
23. [23] Kundi, H., Ates, I., Kiziltunc, E., Cetin, M., Cıcekcioglu, H., Neselioglu, S., Erel, O., Ornek, E., A novel oxidative stress marker in acute myocardial infarction: thiol/disulphide homeostasis. Arm J. Emerg. Med. 33 (2015), 1567–1571.
24. [24] Elman, G., Lysko, H., A precise method for the determination of plasma sulfhydryl groups. Anal. Biochem. 99 (1979), 98–102.
25. [25] Zecca, L., Zucca, F.A., Wilms, H., Sulzer, D., Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26 (2003), 578–580.
26. [26] Durrieu, G., Lau, M.E.L., Rascol, O., Senard, J.M., Rascol, A., Montastruc, J.L., Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin. Auton. Res. 2 (1992), 153–157.
27. [27] Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P., Double, K.L., Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 75 (2005), 109–124.
28. [28] Double, K.L., Ben-Shachar, D., Youdim, M.B.H., Zecca, L., Riederer, P., Gerlach, M., Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24 (2002), 621–628.
29. [29] Muller, T., Do we need a new levodopa?. Neural Regener. Res. 11 (2016), 731–732.
30. [30] Muller, T., Detoxification and antioxidative therapy for levodopa induced neuro-degeneration in Parkinson's disease. Expert Rev. Neurother. 13 (2013), 707–718.
31. [31] Cotzias, G.C., Miller, S.T., Tang, L.C., Papavasililiou, P.S., Levodopa, fertility, and longevity. Science 196 (1977), 549–551.
32. [32] Mena, M.A., Davila, V., Sulzer, D., Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J. Neurochem. 69 (1997), 1398–1408.
33. [33] Murer, M.G., Dziewczapolski, G., Mennalled, L.B., Garcia, M.C., Agid, Y., Gershanik, O., Raisman-Vozari, R., Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43 (1998), 561–575.
34. [34] Yahr, M.D., Wolf, A., Antunes, J.L., Miyoshi, K., Duffy, P., et al. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 22 (1972), 56–71.
35. [35] Muller, T., Muhlack, S., Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients. J. Neural Transm. 121 (2014), 643–648.
36. [36] Muller, T., Muhlack, S., Cysteine decrease following acute Levodopa intake in patients with Parkinson's Disease. Neurosci. Lett. 521 (2012), 37–39.
37. [37] Muller, T., Muhlack, S., Cysteinyl-glycine reduction as marker for levodopa indu-ced oxidative stress inParkinson's disease patients. Mov. Disord. 26:3 (2011), 543–546.
38. [38] Muller, T., Kuhn, W., Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov. Disord. 24 (2009), 929–932.
39. [39] Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., Marsden, C.D., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989), 381–389.
40. [40] Good, P.F., Hsu, A., Werner, P., Perl, D.P., Olanow, C.W., Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57 (1998), 338–342.
41. [41] Perry, T.L., Yong, V.W., Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67 (1986), 269–274.
42. [42] Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden, C.D., Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104 (1997), 661–677.
43. [43] Andersen, J.K., Oxidative stress in neurodegeneration: cause or consequence. Nat. Med. 10 (2004), 18–25.
44. [44] Miller, R.L., James-Kracke, M., Sun, G.Y., Sun, A.Y., Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res. 34 (2009), 55–65.
45. [45] Shukla, V., Mishra, S.K., Pant, H.C., Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci., 2011, 2011, 572634.